IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems
IBA is preferred supplier for a 12-system national PET radiopharmaceutical production network, securing capacity ahead of demand across diagnostics and theranostics
Louvain-la-Neuve, Belgium – October 15, 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced that a leading global producer and distributor of radiopharmaceuticals has selected IBA as preferred vendor for the expansion of its production network in the United States with an order of 12 Cyclone® KIUBE 300 solutions to secure the production of radioisotopes for diagnostic and therapeutic applications.
Industrial capacity has become the gating factor in radiopharmaceuticals today. Clinical pipelines are broadening across both diagnostics and therapy, while supply, licensing and production capacity set the pace at which they reach patients. The new collaboration between this leading global producer and IBA answers that need directly: production capacity secured at network scale in the largest radiopharmaceutical market, with every system configured for fluorine-18 (18F) volume today and for radiometals as the therapeutic pipeline matures. The collaboration represents a capacity commitment made ahead of demand rather than in reaction to it.
This contract covers an order for 12 Cyclone® KIUBE 300 systems, each equipped with multiple Nirta® HCFT 18F helium cooling free targets as well as service like IntegraLab® facility design, installation and commissioning, KARE Portal access, and operator and maintenance training. The systems will be deployed as a national production network across multiple sites in the United States, intended for high-volume commercial PET tracer production with 18F at the core.